Podcasts about bayer healthcare

Get your FREE Cybersecurity Salary Guide: https://www.infosecinstitute.com/form/cybersecurity-salary-guide-podcast/?utm_source=youtube&utm_medium=podcast&utm_campaign=podcastIn this episode of Cyber Work, Ken Zalevsky, founder and CEO of Vigilant Ops, joins us to discuss the importance of a Software Bill of Materials (SBOM) in the medical device industry. Zalevsky shares how SBOMs provide transparency and critical security insights, akin to the ingredients list on food packaging, to help identify and defend against vulnerabilities. We also delve into Zalevsky's extensive career in healthcare cybersecurity, starting from his early tech interests influenced by his father to his pivotal role at Bayer Healthcare. The discussion covers the impact of legacy systems, current security trends, the integration of AI in medical device security, and valuable insights for those looking to build a career in this crucial sector. Tune in to learn more about medical device security and the latest in cybersecurity trends, and get some expert advice straight from a seasoned professional.00:00 Understanding SBOMs in medical devices04:20 The evolution of medical device security07:22 Ken Zalevsky's journey in cybersecurity09:28 Challenges in medical device security13:06 The role of SBOMs in cybersecurity15:56 Implementing SBOMs in organizations18:28 Ken Zalevsky's role at Vigilant Ops22:01 Technical aspects of SBOMs27:14 Legacy devices and security measures28:24 Manufacturer's role in device security30:07 Healthcare industry's response to security threats30:42 Impact of major breaches on policy34:13 Generative AI and machine learning in healthcare security40:22 Skills and certifications for healthcare security careers46:46 Career advice and educational paths49:04 About Vigilant Ops and their services52:15 Outro– View Cyber Work Podcast transcripts and additional episodes: https://www.infosecinstitute.com/podcast/?utm_source=youtube&utm_medium=podcast&utm_campaign=podcastAbout InfosecInfosec's mission is to put people at the center of cybersecurity. We help IT and security professionals advance their careers with skills development and certifications while empowering all employees with security awareness and phishing training to stay cyber-safe at work and home. More than 70% of the Fortune 500 have relied on Infosec Skills to develop their security talent, and more than 5 million learners worldwide are more cyber-resilient from Infosec IQ's security awareness training. Learn more at infosecinstitute.com.

This week, we revisit our interview with Keith Grossman. He currently serves as Chairman of Nevro Corp. (NVRO), Vice-Chairman of Alcon, Inc. (ALC), and Lead Director of Outset Medical, Inc. (OM). Previously, Keith was the CEO and President of Nevro. Keith has over 40 years of experience in the medical device field. He served most recently, and for the second time, as the President, Chief Executive Officer, and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical.   Before Thoratec, he served as President, Chief Executive Officer, and director of Conceptus, a women's health medical device company, leading up to its sale to Bayer Healthcare. Before Conceptus, Keith served as managing director of TPG (Texas Pacific Group), a private equity firm, and was a member of its healthcare investment team. Prior to TPG, Keith served as Thoratec's President, Chief Executive Officer, and director for the first ten years of its growth as a commercial company.  Keith was chronicled in the book “Executive Intelligence: What All Great Leaders Have”, was named among the “Business Leaders to Watch” and the “40 Under 40” lists in the Bay Area and was awarded the Lifetime Achievement Award by his Medical Device CEO peers. Keith received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

Send us a textOn this episode of The New Warehouse Podcast, Kevin sits down with Oda Bolden. Oda is the Director of Supply Chain Network, RSD(Radiology, Sterile, & Disposable) Manufacturing at Bayer Healthcare. With over 35 years at Bayer, Oda provides invaluable insights into supply chain management in the medical industry. From handling warehousing and distribution to tackling labor shortages and optimizing operational efficiency, this conversation dives into how Bayer keeps its supply chain running smoothly. Oda shares how his team navigates sterilization, third-party logistics (3PLs), and technology-driven process improvements.Learn more about Zebra Robotics here. Learn more about Nucor Warehouse Systems here. Follow us on LinkedIn and YouTube.Support the show

In this week's episode, I am joined by Dr. Frank L. Douglas, PH.D., M.D. to discuss the negative impact of anxiety, stress, and discrimination in the workplace. His extensive education and experience allow him to speak with great insight and authority on this important topic. Dr. Douglas believes that personal problems can be reframed to produce better outcomes and increase personal satisfaction. Dr. Douglas is an award-winning industry veteran with three decades of experience in healthcare, the pharmaceutical industry, and entrepreneurship. Dr. Douglas holds a Ph.D. in physical chemistry and an M.D. from Cornell University. He completed his internship and residency in internal medicine at the Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health. In spite of episodes of discrimination, Dr. Douglas became the first Black member to be on the board of management of a top 5 global pharmaceutical company. This makes him an excellent choice for lecturing on these revelatory topics. Additionally, Dr. Douglas served as Executive Vice President, Chief Scientific Officer, and Member of the Board of Management of large pharmaceutical companies such as Aventis SA (now Sanofi, SA). Some of his past experiences include being President and CEO of the Austen BioInnovation Institute in Akron; Chief Scientific Advisor of Bayer Healthcare, AG; Founder and First Executive Director of the MIT Center for Biomedical Innovation; Professor of the Practice at the MIT Sloan School of Management and the Harvard-MIT Division of Health, Science, and Technology. Tune in to this week's episode to learn: The importance of diversity and inclusion in the workplace and how it relates to various aspects of organizational success The relationship between workplace stress and its connection to diversity and inclusion efforts, including employee well-being Potential consequences for organizations that fail to prioritize diversity and inclusion Strategies to enhance productivity through fostering a diverse and inclusive environment Practical approaches for tackling discrimination in the workplace and the role of leadership  Grab your drink of choice and join the conversation! Disclaimer The Healthcare Provider Happy Hour Podcast makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast. The information, opinions, and recommendations presented in this podcast are for general information only and any reliance on the information provided in this podcast is done at your own risk. This podcast should not be considered professional advice. Please speak with your own healthcare practitioner when seeking medical advice. Resources Connect with Dr. Douglas Website: https://safehavendialogues-llc.com/  Sponsorship Mindset Gap: Use referral code JENCAN20 when emailing assist@themindsetgap.com. The Mindset Gap is a boutique consultancy firm arming employees and leaders with mindset tools to increase productivity, bounce forward from adversity, and reset intention. Visit www.themindsetgap.com for more information today. Connect with Jennifer George: @bestobsessed_with_jenn | Instagram Jennifer George | Website @jenngeorge08) | Twitter Jennifer George | Facebook Click here to check out my book about connecting and communicating with patients to empower their experiences! Stay up to date on everything happening with the Healthcare Provider Happy Hour by subscribing to my weekly newsletter at www.jennifergeorge.co  -| The Health Equity Podcast Channel is made possible with support from Bayer G4A. Learn more about how Bayer G4A is advancing equity, access and sustainability at G4a.health -| This episode originally aired on October 17, 2023 on Healthcare Provider Happy Hour. Listen, follow and subscribe here.

This week, we welcome back Keith Grossman. Keith has been a leader in the medical technology industry for more than 35 years. He is currently the Chairman of the Board of Nevro Corporation (NVRO), where he was previously President and CEO from 2019 through April 2023. Prior to Nevro, he was named President and CEO of Thoratec Corp. (THOR) for the second time in 2014. He led the company's return to growth, a 2.5x increase in company value, and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President, and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company's sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company's value before his arrival. Prior to Conceptus, Keith served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec's President, Chief Executive Officer, and director for the first ten years of its growth as a commercial company. Prior to Thoratec, he held a number of commercial and general management roles with companies, including SulzerMedica and American Hospital Supply Corp. He currently also serves as Vice Chairman of Alcon, Inc., and is on the board of Outset Medical, Inc. and previously served as a member of the Board of directors of Intuitive Surgical, Inc., Kyphon, Inc., ViewRay, Inc., Zeltiq, Inc, and a number of privately held medical device companies. Keith received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

Dr. Frank L. Douglas is an award-winning industry veteran with three decades of experience in healthcare, pharmaceuticals, and entrepreneurship. He served as Executive Vice President, Chief Scientific Officer and Member of the Board of Management of large Pharmaceutical companies such as Aventis AG, now Sanofi, SA. Dr. Douglas recently served as CEO of THEVAX Genetics USA Inc. and Member of the Board of TheVax Genetics Vaccine Co. He is also the co-founder of Douglas Ahmed Consulting (DAC). Some of his past experiences include being President and CEO of the Austen BioInnovation Institute in Akron, Executive Vice President, Chief Scientific Officer and Member of the Board of Management of Aventis AG, Chief Scientific Advisor of Bayer Healthcare, AG, Founder and First Executive Director of the MIT Center for Biomedical Innovation, Professor of the Practice in the Massachusetts Institute of Technology (MIT) Sloan School of Management, MIT Departments of Chemistry, Biomedical Engineering and the Harvard-MIT Division of Health Science and Technology.Dr. Douglas holds a Ph.D. in physical chemistry and an M.D. from Cornell University. He did his internship and residency in internal medicine at the Johns Hopkins Medical Institute and a fellowship in neuroendocrinology at the National Institutes of Health. In addition to his impressive career achievements, Dr. Douglas has led clinical trials and presented on healthcare disparities at ROCHE Pharma, UK. He conducted workshops and case study presentations at HBCUs namely at Lehigh University and MIT, the University of Akron, and Weill Cornell Medical School.Dr. Douglas is the founder and CEO of SAFE HAVEN DIALOGUES LLC, and has also authored two groundbreaking books, entitled “Defining Moments of a Free Man from a Black Stream” and “Until You Walk in My Shoes: A Reframing Methodology to Overcome Systemic Discrimination".AWARDS- Global Pharmaceutical Research and Development Director of the Year Award in 2001 and 2004- Lifetime Achievement Award from the National Organization for the Professional Advancement of Black Chemists and Chemical Engineers in 2002- Black History Maker Award in 2007- Geoffrey Beene Foundation and GQ Rockstar of Science, and the Odyssey Award from the Center of Medicine in the Public Interest in 2010- Caribbean Heritage Award for Entrepreneurship in 2011

On this episode, I was joined by Martin Van Trieste, Author of Protecting the Patient at All Costs: The Drug Watch Dogs and is the Former Chief Quality Officer at Amgen and Former CEO at Civica Rx. Martin and I discuss: - Protecting the Patient at All Costs - Quality Leadership and being a Chief Quality Officer in Big Pharma - Supply Chain Security - Generic Drugs and Shortages Martin Van Trieste is an accomplished entrepreneur, board governance expert, executive coach and biopharmaceutical executive. Martin Van Trieste is the Former President and CEO of Civica Rx. Prior to joining Civica Rx, he worked with Amgen, a leading biotechnology company and also previously served as vice president of worldwide quality for Bayer Healthcare's Biological Products Division and vice president of quality assurance for the Hospital Products Division for Abbott Laboratories. Van Trieste has also taken on ventures of his own. He's the founder of Rx-360, an international nonprofit organization that enhances patient safety by increasing security and quality in the biopharmaceutical supply chain. He has also served as the chairman of the Parenteral Drug Association (PDA) Board of Directors and was honored with the 2020 Joseph B. Sprowls Lecturer award. 

In this week's episode, I am joined by Dr. Frank L. Douglas, PH.D., M.D. to discuss the negative impact of anxiety, stress, and discrimination in the workplace. His extensive education and experience allow him to speak with great insight and authority on this important topic. Dr. Douglas believes that personal problems can be reframed to produce better outcomes and increase personal satisfaction. Dr. Douglas is an award-winning industry veteran with three decades of experience in healthcare, the pharmaceutical industry, and entrepreneurship. Dr. Douglas holds a Ph.D. in physical chemistry and an M.D. from Cornell University. He completed his internship and residency in internal medicine at the Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health. In spite of episodes of discrimination, Dr. Douglas became the first Black member to be on the board of management of a top 5 global pharmaceutical company. This makes him an excellent choice for lecturing on these revelatory topics. Additionally, Dr. Douglas served as Executive Vice President, Chief Scientific Officer, and Member of the Board of Management of large pharmaceutical companies such as Aventis SA (now Sanofi, SA). Some of his past experiences include being President and CEO of the Austen BioInnovation Institute in Akron; Chief Scientific Advisor of Bayer Healthcare, AG; Founder and First Executive Director of the MIT Center for Biomedical Innovation; Professor of the Practice at the MIT Sloan School of Management and the Harvard-MIT Division of Health, Science, and Technology. Tune in to this week's episode to learn: The importance of diversity and inclusion in the workplace and how it relates to various aspects of organizational success The relationship between workplace stress and its connection to diversity and inclusion efforts, including employee well-being Potential consequences for organizations that fail to prioritize diversity and inclusion Strategies to enhance productivity through fostering a diverse and inclusive environment Practical approaches for tackling discrimination in the workplace and the role of leadership  Grab your drink of choice and join the conversation! Disclaimer The Healthcare Provider Happy Hour Podcast makes no warranty, guarantee, or representation as to the accuracy or sufficiency of the information featured in this Podcast. The information, opinions, and recommendations presented in this podcast are for general information only and any reliance on the information provided in this podcast is done at your own risk. This podcast should not be considered professional advice. Please speak with your own healthcare practitioner when seeking medical advice. Resources Connect with Dr. Douglas Website: https://safehavendialogues-llc.com/  Sponsorship Mindset Gap: Use referral code JENCAN20 when emailing assist@themindsetgap.com. The Mindset Gap is a boutique consultancy firm arming employees and leaders with mindset tools to increase productivity, bounce forward from adversity, and reset intention. Visit www.themindsetgap.com for more information today. Connect with Jennifer George: @bestobsessed_with_jenn | Instagram Jennifer George | Website @jenngeorge08) | Twitter Jennifer George | Facebook Click here to check out my book about connecting and communicating with patients to empower their experiences! Stay up to date on everything happening with the Healthcare Provider Happy Hour by subscribing to my weekly newsletter at www.jennifergeorge.co 

Synopsis: Theresa Heah, M.D., is the CEO of Intergalactic Therapeutics. Intergalactic is overcoming the limitations of viral-based gene therapy and developing a best-in-class non-viral alternative. Intergalactic uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA (“C3DNA”) molecules designed to provide a potentially safer and more effective solution for patients. Theresa has over two decades of global drug development and commercial experience. She talks about her choice to focus on ophthalmology, where ophthalmology as a therapeutic area is from a drug development perspective, and some of the opportunities she sees ahead for this space. She discusses the importance of having mentors and the emotional aspects of being a CEO. Finally, she dives into the work Intergalactic is doing, where they are from a company building perspective, and how she thinks about driving more access and scale for gene therapies, given the high cost of development and scalability. Since this podcast was recorded, in July 2023, new data from IG-002, Intergalactic's lead program, demonstrated persistent ABCA4 expression in non-human primate retinas over six months after a single administration.This data support plans to advance IG-002 into Phase 1 trials in 2024. Biography: Dr. Heah is an accomplished executive who brings over two decades of drug development and commercial experience, focused primarily in gene therapy and ophthalmology. She most recently served as President and Chief Medical Officer at Kriya Therapeutics, where she launched the ophthalmology division, Kriya Ophthalmology, and was responsible for building its AAV gene therapy portfolio strategy and supporting the company's Series C financing. Prior to joining Kriya, Dr. Heah served as Executive Vice President of Operations and Chief Medical Officer at AsclepiX Therapeutics, where she led the company's Series A financing and advancement of its pipeline products into the clinic. Dr. Heah also previously served as Chief Medical Officer at Applied Genetic Technologies Corporation (AGTC), working to develop gene therapies in ophthalmology and rare diseases. In addition, she has held several leadership positions with increasing responsibility in early-stage private companies (Fovea Pharmaceuticals) and publicly traded companies (Aerie Pharmaceuticals, Allergan, Bayer Healthcare, Sanofi). Dr. Heah earned her M.D. from Guy's, King's and St. Thomas' School of Medicine, King's College, University of London, and her Executive Master's in Business Administration from the European School of Management & Technology (ESMT), Berlin.

Cette semaine, nous revenons sur l'avant-projet de loi « pour une nouvelle société du travail et de l'emploi ». Autrement dit le texte qui définit les missions de France Travail, l'opérateur qui devrait remplacer Pôle Emploi le 1er janvier prochain. On aborde aussi le projet d'accord national interprofessionnel sur le fonctionnement de la branche accidents du travail/maladies professionnelles, conclu après sept séances de négociation et ouvert à la signature jusqu'au 31 mai. Notre focus texte porte sur un accord assez innovant qui vient d'être signé par la direction de Bayer HealthCare et les syndicats CFTC et FO, qui définit les modalités du droit d'expression directe et collective des salariés. Enfin, nous revenons en chiffre sur les actes LGBTphobes liés au travail recensés dans le dernier rapport de SOS homophobie.  Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

A conversation with Kelvin Burton, Martha Henderson, and Graeme McKay from Mercy Ships, an international charity that operates the largest non-governmental ships in the world, providing aid including community health projects. The team discusses the informatics challenges that arise in such a unique environment. Kelvin Burton joined the IS team at Mercy Ships in East Texas in October 1990. He filled many roles in IS over the years and is currently a Business Analyst in the Organizational Project Management Office. For the last 3 years he has been focused on projects intended to improve the hospital efficiency on Mercy Ships, including the Radiology PACS replacement project. Martha first volunteered in 2012 with Mercy Ships in Togo, West Africa. Over the next 10 years she split her time working with the NHS as CT Radiographer and leading the Radiology team onboard the MV Africa Mercy. More recently her focus has been setting up the Radiology department on The Global Mercy while completing her Masters in Applied Global Health. Having previously worked with innovative start-up companies including MedCurrent, Radimetrics as well as industry leaders Bayer Healthcare and JP Morgan Chase, Graeme McKay is combining his experience with a passion for healthcare and technology in his role as CTO and co-founder of Interlinx. Connect with us! You can find our podcast on Apple Podcast, Google Podcasts, Stitcher, or anywhere else you subscribe to podcasts. Please help us out by leaving a review on Apple Podcasts. You can find us on Twitter: @SIIM_Tweets, and individually at @mohannadhussain, @jaynagels, @AliTejaniMD, @arjunsharmarad Visit us! Special Thanks to @RandalSilvey of PodEdit for editing and post-processing support.

Oliver Meier ist ein internationaler Speaker, Businesstrainer und Businesscoach. Seine Schwerpunkte liegen in der Kundenakquise und der Vertriebsstrategie mit einem starken Fokus auf LinkedIn Marketing und Automatisierung. Er sprach, trainierte und coachte auf 4 Kontinenten in Ländern wie Deutschland, der Schweiz, den Niederlanden, Schweden, Österreich, Großbritannien, Polen, den USA, Südafrika, der Türkei, den Vereinigten Arabischen Emiraten und anderen. Seit vielen Jahren trainiert er regelmäßig Vertriebsteams großer Marken wie Amazon, Vodafone, Bayer Healthcare und anderen namhaften Konzernen. Als Unternehmer, und seit mehr als 20 Jahren im internationalen Vertrieb erfahren, ist er stets ergebnisorientiert und sorgt für die zeitnahe Umsetzung seiner Methoden und Systeme. Mit seiner Firma Get More Academy konzentriert er sich auf kleine Unternehmen, Unternehmer und Coaches und zeigt ihnen, wie sie durch LinkedIn und andere Systeme Leads und Neugeschäft generieren und die Gewinne im Vertrieb steigern können. Darüber hinaus auch die Automatisierung von Vertrieb, Marketing und Prozessen. Seine Mission: Vor allem kleine Unternehmen und Unternehmer befähigen, die Möglichkeiten und Systeme unserer Zeit sinnvoll und effizient zu nutzen, um mehr Zeit für die wirklich wichtigen Dinge im Leben zu haben. Das von ihm 2018 veröffentlichte Buch "King of Contacts" wurde bei Amazon zum Nr. 1 Bestseller. Webseite: https://getmoreacademy.de/

In episode #5 of the podcast, we meet with Carlos Diaz, CEO of Synapse Research in Spain, a specialist SME managing complex projects in IMI and Horizon 2020 (considered the number one SME), such as EHDEN, and formerly an economist and business administrator. Joining him is Johann Proeve, a biologist by training, who spent 36 years in clinical data management at Bayer Healthcare, and who ran the global data management organisation for 15 years, and who worked within IMI1 EHR4CR, and following retirement came back to Bayer to work in EHDEN. He is also the CSO of Cyntegrity, a risk-based quality management company. Carlos and Johann co-lead EHDEN's Work Package 6 focusing on value propositions, community, stakeholder engagement, education and training, and sustainability. Both Carlos and Johann initially explore the emerging community of multiple entities and organisations in Europe, driven by the adoption of the OMOP common data model (CDM), and now having also worked on evidence generation based on this foundation. The coordination of the Data Partner and SME community via a Community Manager has been critical to this evolution, recognising the specific nuances of Europe, though work remains to be done in terms of being self actualising as a community from local to regional, with a levelling up in terms of geographical through to chronic to rare diseases representation. The discussion then explores the thinking behind the startup mentality ('running the project like a business'), especially as EHDEN now has two years left in the IMI phase, focusing on value streams and the establishment of the EHDEN not-for-profit entity, but most importantly the incentives driving everyone's involvement and the need to develop relationships. Lastly, we focus on a thought experiment considering what success would look like two years after the IMI phase ends, in 2026, centering on a revolution in real world research within a self actualised, open science community. The views expressed by the participants are personal and not necessarily reflective of their organisations.

In this episode, we are joined by Bharti Rai, an accomplished and versatile leader with 25 years of experience in healthcare and Big 4 management consulting. She has been at the forefront of strategy, business, and digital transformations to champion data-driven decision-making and customer-centricity with a dynamic and collaborative leadership style. We discuss the biggest challenges for pharma and life sciences companies during commercial transformation and the consequences for companies who refuse to evolve. Tune in as Bharti shares how companies can measure their success in the commercial process and what kind of mindset companies should adopt to achieve transformation successfully.     IN THIS EPISODE:   [02:04] What role does culture and mindset play in commercial transformation? [07:45] Bharti shares the four biggest digitization challenges for pharma and life sciences companies. [16:20] How macro-level areas must be carefully navigated when driving maturity across people, processes, and systems. [20:29] Measuring and tracking the success of the digitization process. [25:11] What should pharma and life sciences companies look for when building their teams and the talent pool.   KEY TAKEAWAYS:   Digital transformations usually start top-down with leadership and then progress to the rest of the functions. Getting the leadership to believe in it is not enough. It has to permeate the rest of the organization. Pharma and life sciences companies understand that digitization is inevitable and necessary, but they struggle to figure out how to do it effectively and with lasting effect. Most companies are solely focused on technology and miss out on other essential elements in digital transformation, such as the importance of people, evolution, talent, mindset, and culture.   LINKS MENTIONED:   Bharti Rai on LinkedIn: https://www.linkedin.com/in/raibharti/   Axtria on LinkedIn: https://www.linkedin.com/company/axtria/   BIO: Bharti Rai is an accomplished and versatile leader with 25 years of experience in healthcare and Big 4 management consulting. She has been at the forefront of strategy, business, and digital transformations to champion data-driven decision-making and customer-centricity with a dynamic and collaborative leadership style.   She joined Novartis in 2018. As the VP of Commercial Operations, Insights, Data, and Analytics, she led the vision and creation of the US function from the ground up and transformed it from a back-office function to a strategic one that helped with decision-making across the business.    Prior to Novartis, she held roles at Bayer Healthcare and Deloitte Consulting across processors engineering, digital health, commercial, operations, and data. She is recognized as an industry thought leader and is the recipient of numerous industry awards. 

Ever wonder what it takes to be successful in the pharmaceutical industry? Hear firsthand Jeff Bova, Chief Commercial Officer at UroGen Pharma, as he discusses his career path along with his advice on finding success within the pharmaceutical industry. Jeff is a graduate of the University of Cincinnati and Xavier University and has held positions at Bayer Healthcare and Bayer Pharmaceuticals before joining the UroGen Pharma team. 

Most likely everyone reading this has been affected by cancer or knows someone who has had cancer.  Using natural cell degradation, today's guest and the team at Arvinas are treating previously undruggable diseases like cancer and Parkinson's. Their goal is to cure cancer or at a minimum, reduce it to a disease where you take your medication and continue living a full life without the terrible side effects of today's treatments.  Dr. Ian Taylor, Chief Science Officer at Arvinas, explains how his team is accomplishing this with PROTAC. Arvinas is a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. If you are hoping for another treatment for cancer besides historical approaches (like chemotherapy), you need to listen to what Dr. Taylor has to say. It's innovating and extremely exciting.  More about Dr. Ian Taylor:Dr. Taylor came to the company after nearly 10 years at Pfizer Oncology, most recently as an Early Development Team Leader. In this role, Dr. Taylor was responsible for leading a cross-functional drug development team that conducted Phase 1 and Phase 2 clinical trials for multiple assets in several cancer indications. His initial role at Pfizer Oncology was as Senior Director of Translational Oncology. In this role, he was responsible for directing translational science activities, which included designing and executing translational research plans and leading companion diagnostic partnerships for programs in both preclinical and clinical (Phase 1 -3) stages. Prior to Pfizer, Dr. Taylor worked at Bayer Healthcare, Pharmaceuticals, holding positions of increasing responsibility, including Vice President of Cancer Biology. In this position, he led the department responsible for all biology aspects of small molecule drug discovery of cancer therapeutics in the mechanistic areas of signal transduction, cell cycle regulation, angiogenesis and apoptosis. During his tenure, the Cancer Biology group delivered numerous molecules to the Development organization. He also started and led the Biomarker group, which contributed to the development of sorafenib. Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in Molecular Biology and Genetics from Harvard University. He also completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).Show noteshttps://www.arvinas.comArvinas treatment pipeline: https://www.arvinas.com/pipeline-programs/pipelineBe a guest on the show: https://docs.google.com/forms/d/e/1FAIpQLSeEU7Owi8VDv30hzmWbj4JsXPKyfsWvKXHMeghEAyirAbR18A/viewformMusic by keldez

We conclude our conversation with Audrey Arbeeny, Founder, CEO, and Executive Producer at Audiobrain, a sonic branding agency based in New York. We talk about how sonic branding is a foundation for brand equity, how brands and other clients are treating sonic branding in their branding strategy, the crucial issue of good sound vs. bad sound, and exciting things that are brewing in the sonic branding world today. Audrey is an Emmy-award winning sonic brander.  She is also the CEO and Executive Producer of Audiobrain, a global leader in sonic branding.  Audiobrain has worked with companies and on projects such as Microsoft’s Xbox 360, Google, Holland America Line, IBM, KIA Motors Corp, Bayer Healthcare, Logitech, Microsoft, Toshiba, and many more. If you want to get a hold of Audrey you can find her on Linkedin and Twitter as well as her official website Audiobrain.com.  If you’re enjoying these conversations on sound in marketing then I know you’ll love this.  I have a course on Sound’s Power and Influence in Marketing that you can enroll in at www.soundinmarketing.com.  Years of research has gone into this course and I’m confident that you’ll learn a lot.  My goal is that you’ll be able to take this information and begin applying it to your brand or company.  And if you need further help, I also consult! So head on over to the site to preview the trailer, view the curriculum, and sign up for a dose of sound in marketing.   You can find the Sound In Marketing Podcast on all the major podcast channels like iTunes, Spotify, Google Play, iHeart Radio, Pandora, and Stitcher so don’t forget to share it with your friends, follow, and rate it.  More people should know about this stuff.  I know you know that now.  For inquiries on sonic branding and sonic branding consultations, you can find me at Dreamr Productions www.dreamrproductions.com, Linkedin, Twitter, and Facebook.  You can also email me at jeanna@dreamrproductions.com.  This episode was produced by Dreamr Productions and hosted, written, and edited by me, Jeanna Isham. Let’s make this world of sound more intriguing, more unique, and more and more on brand.

Today’s episode is about sonic branding.  I’m joined by Audrey Arbeeny, the brain behind Audiobrain.  We talked about definitions of sonic branding, intentional sound, what’s important and not important in your sound, and who’s buying. Audrey is an Emmy-award winning sonic brander.  She is also the CEO and Executive Producer of Audiobrain, a global leader in sonic branding.  Audiobrain has worked with companies and on projects such as Microsoft’s Xbox 360, Google, Holland America Line, IBM, KIA Motors Corp, Bayer Healthcare, Logitech, Microsoft, Toshiba, and many more. If you want to get a hold of Audrey you can find her on Linkedin and Twitter as well as her official website Audiobrain.com.  If you’re enjoying these conversations on sound in marketing then I know you’ll love this.  I have a course on Sound’s Power and Influence in Marketing that you can enroll in at www.soundinmarketing.com.  Years of research has gone into this course and I’m confident that you’ll learn a lot.  My goal is that you’ll be able to take this information and begin applying it to your brand or company.  And if you need further help, I also consult! So head on over to the site to preview the trailer, view the curriculum, and sign up for a dose of sound in marketing.   You can find the Sound In Marketing Podcast on all the major podcast channels like iTunes, Spotify, Google Play, iHeart Radio, Pandora, and Stitcher so don’t forget to share it with your friends, follow, and rate it.  More people should know about this stuff.  I know you know that now.  For any further inquiries, you can find me at Dreamr Productions www.dreamrproductions.com, Linkedin, Twitter, and Facebook.  You can also email me at jeanna@dreamrproductions.com.  This episode was produced by Dreamr Productions and hosted, written, and edited by me, Jeanna Isham. Let’s make this world of sound more intriguing, more unique, and more and more on brand.

46. The Art of Productive Screen Time, host William Glass sits down with Laura Page-Hamelin & Graeme McKay, co-founders of Artebula. Together they discuss the power of creativity and how promoting creative children lead to future innovators. From there we explore the challenges facing parents and children with the current content platforms and how Artebula is focused on promoting productive screen time by combining technology, art, and science. You’ll also learn the challenges and benefits of going from solopreneur to teampreneur and how to effectively work as a team across multiple continents. Laura Page-Hamelin is a passionate businesswoman and entrepreneur. Laura worked in the corporate world as a marketer but felt most comfortable being an entrepreneur. When her fourth child was born with a rare auto-immune disorder she decided to stay home permanently and to fund this choice she used her digital marketing talents to found a successful, boutique digital marketing agency, Social Jibber Jabber. In 2018, Laura identified a pain point in the children’s art and education market and with a five thousand dollar government grant began the foundations for what would later become Artebula Inc. Graeme McKay is the technology lead at Artebula and brings significant experience in both healthcare informatics and finance product design and development. Graeme has worked with innovative start-up companies including eFilm and Radimetrics, as well as industry leaders Bayer Healthcare and JP Morgan Chase. Graeme holds a Bachelor's degree in Applied Computing from the University of Strathclyde as well as being a certified Scrum Product Owner. Website: https://www.artebula.com LinkedIn: https://www.linkedin.com/company/artebula-inc/ __ Visit SiliconAlleyPodcast.com - Instagram: https://instagram.com/siliconalleypodcast - LinkedIn: https://linkedin.com/company/siliconalleypodcast - YouTube: https://www.youtube.com/channel/UCSF39MO5e4z1SX9tYZEhNgA Theme music is Million Voices by Brett Miller - www.brettmillerofficial.com Ostrich is a personal finance app that uses the power of positive social accountability to help you define, set, & achieve your financial goals. Sign Up for Ostrich at https://www.getostrich.com Instagram: https://instagram.com/theostrichapp LinkedIn: https://LinkedIn.com/company/theostrichapp Silicon Alley is a Financial Glass Production --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/silicon-alley/message Support this podcast: https://anchor.fm/silicon-alley/support

Our guest this week is Bob Potts. Bob holds a MFA in Industrial Design and was Design Director for a series of corporate groups responsible for design development of diagnostic medical products including Corning Medical and Bayer Healthcare. He holds sixteen patents and has been a frequent presenter at international industry conferences, design seminars, and design programs and business schools. His design groups have won sixty international awards for design excellence and have been featured in ID, Print, Communication Arts, Axis, NIKKEI DESIGN, Business Week, and Fortune. You can follow him on Instagram @bobatharbor. For show notes visit: https://kk.org/cooltools/bob-potts-industrial-designer/

In today's episode, Kaeli discusses herself and her journey into the aesthetics field. She also talks about her personal mission and lets us in on why it's important to fully optimize your team to maximize your growth and income. After graduating, Kaeli was recruited for a sales position with Bayer Healthcare. This allowed her to learn the intricacies of working for a Fortune 500 company, and how corporations in general operate. Kaeli was then recruited to an aesthetics company where she found her true passion. She moved up the ladder into sales management, then to sales director heading a team of 15 women. While she loved her job and team, with two small children at home she ultimately decided to make a change for her family. Always seeing her superpower as being able to see the big picture, as well as having an entrepreneurial spirit, Kaeli began KLC Consulting. With a passion for team building and team culture, Kaeli found her focus in helping to build her clients' practices. During this period, she found that doctors are often lacking the skills needed to be CEO and the time to learn them. Here, Kaeli noticed an opportunity often missed. Practice managers are underutilized and undervalued. To expand and scale the reach of your business, develop the team you already have. What people are learning at conferences is outdated for the practices of today and we need to step up and innovate. Kaeli's mission is to elevate the voices of practice managers and give them the platform and tools they need to help grow their business. It's time to stop looking externally for solutions. Optimize who and what you already have to build the strong foundations of leadership and culture within your business.   Book a Strategy Call with Kaeli Tribe of Fierce Aesthetic Leaders on Facebook KLC Consulting Website Kaeli on Instagram Kaeli on LinkedIn Video Link to this episode

COVID-19 has hit minority populations particularly hard, delivering a wake-up call to healthcare policymakers. How can we change the system to help marginalized communities get access to the care they need? Dr. Bob speaks with Dr. Frank L. Douglas, who describes his experiences fighting racism within the healthcare industry. And we hear from a member of the LGBTQ+ community battling the stigma of HIV. Guest:Frank L. Douglas, M.D., Ph.D. Dr. Frank L. Douglas has over thirty years of experience in the healthcare and pharmaceutical industry. Most recently, Dr. Douglas served as CEO of TheVax Genetics USA Inc. and Member of the Board of TheVax Genetics Vaccine Co. Born in Guyana in 1943, Dr. Douglas traveled to America on a Fulbright scholarship to attend college. After completing his studies and receiving his medical degree, he went on to teach clinical pharmacology at the University of Chicago’s Pritzker School of Medicine. He’s also held positions as Chief Scientific Advisor of Bayer Healthcare, First Executive Director of the MIT Center for Biomedical Innovation, and co-founder of Douglas Ahmed Consulting.In 2019, Dr. Douglas published his memoir Defining Moments of a Free Man from a Black Stream. It describes his experiences navigating racism within both university and professional settings in America. Dr. Douglas earned his doctorate in physical chemistry and his medical degree from Cornell University in Ithaca, New York. Hosts:Terry Wilcox, Executive Director, Patients RisingDr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.Kate Pecora, Field Correspondent Links:Frank L. Douglas, M.D., Ph.D. Defining Moments of a Free Man from a Black StreamCOVID-19 Will Help Us Overhaul Clinical TrialsPatients Rising Concierge Need help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.orgThe views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising. 

“We saw that women didn’t have the confidence to step up, so we were determined to change that for #GenerationEquality so that women of the future and women today have a better shot at being in senior levels roles.” - Denise D’Agostini On March 8th, LiveGirl celebrated International Women's Day (IWD) with the theme: “Generation Equality: Realizing women’s rights for an equal future.” For this year's celebration, Sheri and Olivia sit down with Denise D’Agostini, Co-Founder of Her New Standard, and her daughter, Lauren to talk about the importance of challenging gender norms and empowering each other.  IWD is important because despite some progress, real change has been agonizingly slow for the majority of women and girls in the world. Today, not a single country can claim to have achieved gender equality. Multiple obstacles remain unchanged in law and in culture. And women and girls continue to be undervalued. Check out our conversation where Denise and Lauren share about the inspiration behind Her New Standard, the “playbook” for #nextgen leaders and the top things holding women and teens back.  Lauren is a 16-year-old high schooler, who attends Somers New York High School. Denise has 25 years of experience in Pharma, which includes serving as the Head of HR for both Bayer HealthCare and Ciba Specialty Chemicals. She later co-founded Her New Standard in 2013, stemming from her passion in developing women leaders & igniting confidence so that each individual reaches their greatest potential. Denise’s clients range from Fortune 500 to start-ups. Along with serving as HR Leader and Executive Coach at Her New Standard, Denise is ALSO an adjunct instructor at Cornell University, the ILR School of Human Capital Development.  Join #GenerationEquality. Be the first, the youngest, the best, and make sure no one is left behind. The future we create for women and girls up to all of us.

A few years ago, I had the privilege of sitting down and talking with serial medtech entrepreneur Paul Buckman, who at the time, was CEO of Conventus Orthopedics. Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway Medical Technologies (which sold to Bayer HealthCare), and Devax (which sold to Biosensors International). From 2004 through 2006, Buckman served as President of the Cardiology Division of St. Jude Medical. Before joining St. Jude, he served as Chairman and CEO of ev3, a company that Buckman co-founded and was later acquired by Covidien for $2.5 billion dollars in 2010.Paul has worked in the medical device industry for over 35 years, including 10 years at Scimed Life Systems and Boston Scientific where he held several executive positions before becoming President of the Cardiology Division at Boston Scientific in January of 2000. Buckman received a BA degree in business administration and an MBA degree from Western Michigan University. Here are a few of the things we’re going to learn in this interview with Paul:- Of all the medtech startups that Paul’s been a part of, the two that are closest to his heart.- Two of the many key learnings that Paul recalls during his time helping to build Scimed.- When it comes to product development for medtech startups, why it’s critical to be ruthless about prioritization.See more...

Strg-Alt-Entf hat auf der hub.berlin gleich zwie Premieren gefeiert. Gemeinsam mit Angeli Moeller von Bayer Healthcare haben wir die erste englische Episode und zugleich die erste Live-Episode aufgenommen. Wir wollten von Angeli wissen, wie sich Künstliche Intelligenz auf das Gesundheitswesen und die Pharmaindustrie auswirkt, was die Aufgaben eines Data Scientists bei Bayer so sind und wie Gesundheitsversorgung in Zukunft aussehen wird.

Show Notes: Martin VanTrieste, President & Chief Executive Officer, Civica - Martin VanTrieste brings over 35 years in the pharmaceutical industry – focusing on manufacturing and quality. He was ranked #2 on the 2018 Medicine Maker Power List of Industry Influencers. Martin VanTrieste was the Chairman of the Parenteral Drug Association (PDA) Board of Directors. The PDA represents over 10,000 members, and is the leading global facilitator of scientifically sound, practical technical information, quality systems and expertise to advance Pharmaceutical / biopharmaceutical manufacturing science and regulation so members can better serve patients. He recently retired as the senior vice president of quality at Amgen. He was responsible for quality assurance, quality control, compliance, operational excellence, environment, health and safety along with training at Amgen. Prior to joining Amgen, VanTrieste was with Bayer Healthcare’s Biological ProductsDivision as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division. While at Abbott, VanTrieste held various positions in Quality, Operations, and Research and Development. He started his career at Abbott in 1983 after obtaining his Pharmacy degree from Temple University School of Pharmacy. He is the founder of Rx-360 and first Chairman of the Board of Directors. Rx-360 is a nonprofit international supply chain organization that enhances patient safety by increasing the security and quality in the biopharmaceutical supply chain. VanTrieste has been actively involved with various professional and trade organizations, including, United States Pharmacopeia (USP), Pharmaceutical Quality Research Institute (PQRI), Pharmaceutical Research and Manufactures of America (PhRMA), and AdvaMed. PharmaVoice in 2012 named VanTrieste as one of the 100 most inspiring people inthe pharmaceutical industry, calling him “a man with a mission”. The MedicineMaker in 2016, 2017 and 2018 named him one of the most influential people in the world of drug development and manufacture saying, “he is known throughoutindustry for his work on advancing quality assurance and helping to ensure a more reliable supply of high-quality medicines.”    Civica Webpage: https://civicarx.org/    ASCP's call for proposals page - share your expertise with our members in 2019!  https://www.ascp.com/page/callforproposals See omnystudio.com/listener for privacy information.

Show Notes: Martin VanTrieste, President & Chief Executive Officer, Civica - Martin VanTrieste brings over 35 years in the pharmaceutical industry – focusing on manufacturing and quality. He was ranked #2 on the 2018 Medicine Maker Power List of Industry Influencers. Martin VanTrieste was the Chairman of the Parenteral Drug Association (PDA) Board of Directors. The PDA represents over 10,000 members, and is the leading global facilitator of scientifically sound, practical technical information, quality systems and expertise to advance Pharmaceutical / biopharmaceutical manufacturing science and regulation so members can better serve patients. He recently retired as the senior vice president of quality at Amgen. He was responsible for quality assurance, quality control, compliance, operational excellence, environment, health and safety along with training at Amgen. Prior to joining Amgen, VanTrieste was with Bayer Healthcare's Biological ProductsDivision as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division. While at Abbott, VanTrieste held various positions in Quality, Operations, and Research and Development. He started his career at Abbott in 1983 after obtaining his Pharmacy degree from Temple University School of Pharmacy. He is the founder of Rx-360 and first Chairman of the Board of Directors. Rx-360 is a nonprofit international supply chain organization that enhances patient safety by increasing the security and quality in the biopharmaceutical supply chain. VanTrieste has been actively involved with various professional and trade organizations, including, United States Pharmacopeia (USP), Pharmaceutical Quality Research Institute (PQRI), Pharmaceutical Research and Manufactures of America (PhRMA), and AdvaMed. PharmaVoice in 2012 named VanTrieste as one of the 100 most inspiring people inthe pharmaceutical industry, calling him “a man with a mission”. The MedicineMaker in 2016, 2017 and 2018 named him one of the most influential people in the world of drug development and manufacture saying, “he is known throughoutindustry for his work on advancing quality assurance and helping to ensure a more reliable supply of high-quality medicines.”    Civica Webpage: https://civicarx.org/    ASCP's call for proposals page - share your expertise with our members in 2019!  https://www.ascp.com/page/callforproposals See omnystudio.com/listener for privacy information.

Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He's joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals, and Dr Chandra Ramanathan at Bayer Healthcare. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

Our guest on this segment is 30-year veteran of the health and wellness communications industry. VINCE PARRY is the founder of the Parry Branding Group, and the author of Identity Crisis. In it he shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Vince was previously the Chief Branding Officer at inVentiv Health, the Founder and President of Y Brand, the Founder and President of GSW NY and the Chief Creative Officer at Sudler & Hennessey. He's appeared on NBC Nightly News with Brian Williams and BBC radio, has been featured in Medical Marketing and Media, PharmaVoice, Pharmaceutical Executive, and MedAdNews, and guest lectures at the Rutgers Pharmaceutical MBA program on healthcare branding. In his latest book, Identity Crisis, Parry shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Parry weaves examples from his work with industry leaders such as Merck, Bayer Healthcare, and Maimonides Medical Center, and reveals how differentiating healthcare brands have shaped our choices. By incorporating how we identify with illness and wellness into his innovative branding strategies, he has redefined how we make purchasing decisions to improve our lives and find relief. VINCE PARRY Parry Branding Group http://parrybrandinggroup.com/ (646) 850-4537 Learn more about your ad choices. Visit megaphone.fm/adchoices

Our guest on this segment is 30-year veteran of the health and wellness communications industry. VINCE PARRY is the founder of the Parry Branding Group, and the author of Identity Crisis. In it he shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Vince was previously the Chief Branding Officer at inVentiv Health, the Founder and President of Y Brand, the Founder and President of GSW NY and the Chief Creative Officer at Sudler & Hennessey. He's appeared on NBC Nightly News with Brian Williams and BBC radio, has been featured in Medical Marketing and Media, PharmaVoice, Pharmaceutical Executive, and MedAdNews, and guest lectures at the Rutgers Pharmaceutical MBA program on healthcare branding. In his latest book, Identity Crisis, Parry shares keen insights into the success of everyday brands and describes the keys to establishing brand preferences for medications and wellness goods. Parry weaves examples from his work with industry leaders such as Merck, Bayer Healthcare, and Maimonides Medical Center, and reveals how differentiating healthcare brands have shaped our choices. By incorporating how we identify with illness and wellness into his innovative branding strategies, he has redefined how we make purchasing decisions to improve our lives and find relief. VINCE PARRY Parry Branding Group http://parrybrandinggroup.com/ (646) 850-4537 Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, hear what Mary Myers, director of training and development at Bayer Healthcare, on what she thinks will be the key training trends to watch. As president of the Life Sciences Trainers & Educators network (LTEN), she also discusses how LTEN is preparing trainers for what’s ahead in the coming months and shares an uplifting message for life sciences training professionals.

Job seekers with ADD: Essentials for Managing the Search Process and Ensuring the Best Job Fit Lisa Noble is the founder of Career Connectors LLC. A graduate of the University of Virginia, she has 15 years of experience as a hiring manager for Fortune 500 companies (IBM, Bayer Healthcare and Prudential) and top WPP marketing agencies, giving her deep insight into what HR recruiters and managers are looking for in candidates they hire. After years of leading teams of young people, creating career paths and grooming them for their next employer or role, Lisa created Career Connectors, a service designed to help students and job seekers see their own value and find opportunities that best fit their personality, skills and ambitions. 1. How prevalent is ADD or ADHD among job seekers, and why? 2. What if your client doesn’t tell you they have ADD/ADHD, or doesn’t know themselves? Are there behaviors or other indicators a coach can look for? give us some examples 3. What are some common challenges unique to job seekers with ADD/ADHD? How are they different from other job seekers? 4. What does this mean for the Career Discovery process? How can you help your clients identify their ADHD strengths and make sure the industries, companies and roles they are considering play to these strengths? 5. You mentioned earlier that executive function, or the ability to prioritize and organize activities is a particular challenge for job seekers with ADD/ADHD. This is a major part of conducting a successful job search. What sorts of tools do you use with these clients to help them manage the process? 6. Everyone has a bit of anxiety as they present themselves to potential employers. What sorts of negative self-talk do job seekers with ADD/ADHD engage in, and how can a career coach help them? 7. What sorts of work environments and roles are best for candidates with ADD/ADHD? 8. In school, an ADD/ADHD diagnosis often entitles students to accommodations like extra time on tests, quiet places to take tests and even note takers. Can a candidate request accommodations from their employer? How and when might they make this request? 10. Are there differences in the way you might coach recent college grads as compared to career changers with ADD/ADHD?

Job seekers with ADD: Essentials for Managing the Search Process and Ensuring the Best Job Fit Lisa Noble is the founder of Career Connectors LLC. A graduate of the University of Virginia, she has 15 years of experience as a hiring manager for Fortune 500 companies (IBM, Bayer Healthcare and Prudential) and top WPP marketing agencies, giving her deep insight into what HR recruiters and managers are looking for in candidates they hire. After years of leading teams of young people, creating career paths and grooming them for their next employer or role, Lisa created Career Connectors, a service designed to help students and job seekers see their own value and find opportunities that best fit their personality, skills and ambitions. 1. How prevalent is ADD or ADHD among job seekers, and why? 2. What if your client doesn’t tell you they have ADD/ADHD, or doesn’t know themselves? Are there behaviors or other indicators a coach can look for? give us some examples 3. What are some common challenges unique to job seekers with ADD/ADHD? How are they different from other job seekers? 4. What does this mean for the Career Discovery process? How can you help your clients identify their ADHD strengths and make sure the industries, companies and roles they are considering play to these strengths? 5. You mentioned earlier that executive function, or the ability to prioritize and organize activities is a particular challenge for job seekers with ADD/ADHD. This is a major part of conducting a successful job search. What sorts of tools do you use with these clients to help them manage the process? 6. Everyone has a bit of anxiety as they present themselves to potential employers. What sorts of negative self-talk do job seekers with ADD/ADHD engage in, and how can a career coach help them? 7. What sorts of work environments and roles are best for candidates with ADD/ADHD? 8. In school, an ADD/ADHD diagnosis often entitles students to accommodations like extra time on tests, quiet places to take tests and even note takers. Can a candidate request accommodations from their employer? How and when might they make this request? 10. Are there differences in the way you might coach recent college grads as compared to career changers with ADD/ADHD?

Tough Talk with Tony Gambone with his guest Marlin Daniels & Jeremy Britton   Marlin Daniels is an accomplished sales executive with 20 years of award winning experience in sales and business development. Most recently, Marlin's experience came from the Pharmaceutical industry where he served in different sales and sales management roles for top companies like Bristol Meyers Squibb, Bayer Healthcare, Praxair Healthcare and Amylin Pharmaceuticals. In those roles, he went above and beyond the norm, surpassing sales goals and consistently being ranked among the top performers in the country. Marlin is now bringing his experience and expertise to MONEY-fax.com as head of sales and business development.http://money-fax.com/about-the-hosts/ Jeremy Britton was born into a poorer family and decided he wanted to become rich. He left home found a millionaire mentor and started a financial planning business at age 19. Over the next 15 years Jeremy made millions of dollars for his clients and himself, but then some "critical moments" made him reassess his priorities. A heart attack at age 33, followed by divorce made Jeremy realise that a singular focus on making money had cost him his health and his relationships. Jeremy realised that *True Wealth* was having a balance in all areas, and devoted the next few years of his life to health, happiness and spirituality. Quitting smoking, alcohol, coffee, meat and dairy, Jeremy learned meditation, Reiki, EFT, NLP and hypnotherapy. With a balance of left-brain business analytics and right-minded life skills, Jeremy now teaches life balance for entrepreneurs who want more: more happiness, better relationships, more time, more cash and more freedom.  

Workshop Wednesdays with Tony Gambone and his guest Ronald Joseph Kule, Holly Thompson & Marlin Daniels Ronald Joseph Kule sold products and services well enough to afford travel through 35 countries. In 17 countries, including China and Russia, I also delivered seminars, fundraising events and speaking engagements.Through the years, my poetry, short stories and newspaper articles found publication here and there. In between, I trained in acting at the L.A. Academy of Dramatic Arts under Fred Cook; drawing and painting at Mission: Renaissance Art Academy under Larry Gluck; and audited screenwriting classes at Hollywood Screenwriter Workshops, where I met Oscar-winner Ernie Lehman (North By Northwest) and other professional mentors.In 2009, A native of Texas, Holly earned her degree in Business Administration from The University of Texas and her Master of Business Administration from Harvard University (2015). She has been a regular contributor for Seeking Alpha since 2011 and a blogger for The Motley Fool since April of 2013, as well as a World Contributor for TheDailyJournalist.com. When not working, she volunteers her time as the Vice President and Fundraising Chair for Gulf Coast Mensa.http://money-fax.com Marlin Daniels is an accomplished sales executive with 20 years of award winning experience in sales and business development. Most recently, Marlin's experience came from the Pharmaceutical industry where he served in different sales and sales management roles for top companies like Bristol Meyers Squibb, Bayer Healthcare, Praxair Healthcare and Amylin Pharmaceuticals. In those roles, he went above and beyond the norm, surpassing sales goals and consistently being ranked among the top performers in the country. Marlin is now bringing his experience and expertise to MONEY-fax.com as head of sales and business development.http://money-fax.com

John DeStefano Jr., outgoing mayor of New Haven, and Richard Levin, outgoing president of Yale University, reflect on their 20-year partnership to knit together university and city. At the close of the DeStefano-Levin era, we ask: What is the legacy of this extraordinary partnership? What will it mean for New Haven’s future? Moderated by Douglas Rae, Richard S. Ely Professor of Management & Professor of Political Science. John DeStefano, Jr. John DeStefano, Jr. was sworn in as the 49th Mayor of New Haven on January 1, 1994. He is serving his 10th term in office. Mayor DeStefano has worked hard and successfully to strengthen the academic achievement of public school students, to build a vibrant mixed use city center, a competitive economic base, strong neighborhoods and a community culture of traditional values and social tolerance. During Mayor DeStefano’s tenure virtually every public school has been rebuilt under the $1.5 billion Citywide School Construction Program. Key features of the school construction program have supported universal pre-k services, the largest inter-district enrollment and magnet school program in the State, college level lab and technology facilities and great architecture. In 2009, the Mayor and school board, of which he is a member and the appointing authority, announced the School Change Initiative. Supported by a ground breaking agreement with the New Haven Federation of Teachers, the City has launched a reform initiative whose key strategies are a portfolio approach to school management, a focus on teacher talent through a progressive teacher evaluation construct and a commitment to see that every child has the aspiration and is prepared for and able to complete college. Since taking office in 1994 the City center has undergone a dramatic transformation into a mixed use community of some 12,000 residents. Anchored by the Mayor’s support of University, Hospital and medical center expansion, New Haven has emerged as a national center of life and bio science businesses. Downtown commercial, residential and retail occupancies stand at record lows. In 2010 the US Department of Transportation announced funding of the Downtown Crossing project which will remove a 1960’s era limited express highway that has divided the central business district from the City’s principal rail station and rapidly growing medical research, clinical and office district. The project will double the size of the downtown. Neighborhoods have been strengthened as the city has managed housing stock to mixed income and use models, promoted commercial corridors, street smart infrastructure and public improvements. The City has decentralized police management districts, promoted the use of neighborhood based collaborations and a robust civic culture. That civic culture has resulted in a welcoming and inclusive community through initiatives such as the Elm City Resident Card that provides identification cards and access to public services for all residents of the City. Under the Mayor’s leadership, the City has sponsored the organization and capitalization of a community development bank whose mission supports the unbanked and promotes financial literacy. New Haven boasts an incredibly vibrant culture of economic and social entrepreneurship. Mayor DeStefano has served as the President of the Connecticut Conference of Municipalities and the National League of Cities, the oldest and largest organization representing America’s cities and towns. During his tenure New Haven has been named an ‘All America City’ three times. Mayor DeStefano is the son of a New Haven police officer and a lifelong City resident. John and his wife Kathy DeStefano met at the University of Connecticut as undergraduates, where he also earned a Masters in Public Administration. Kathy is a first grade teacher and they are the parents of two sons. Richard C. Levin Richard C. Levin, Frederick William Beinecke Professor of Economics, has been Yale’s President since 1993. He received his B.A. from Stanford University in 1968 and studied politics and philosophy at Oxford University, where he earned a B.Litt. degree. He received his Ph.D. from Yale in 1974 and joined the Yale faculty. Before becoming president, he chaired the economics department and served as dean of Yale’s Graduate School of Arts and Sciences. In August, Mr. Levin announced that he will step down as President of the University at the end of the current academic year, his twentieth year of service. Exciting ventures to improve the University locally, nationally, and internationally have been a hallmark of Mr. Levin’s presidency. Close to home, his goals have included improving the campus infrastructure, and the University has invested over $5 billion in the renovation and construction of its facilities. Strengthening connections to the City of New Haven has led to innovative partnerships that have advanced economic development and encouraged home ownership in the City. In fall 2010, Yale joined with the Community Foundation of Greater New Haven and the City to announce New Haven Promise, a visionary scholarship and support program for city residents who graduate from a public school in the city and attend college in Connecticut. In mid-June 2007, the University purchased the Bayer HealthCare complex, a property with over 500,000 square feet of state-of-the-art research space, as well as office buildings, warehouses and other facilities. Launching and enhancing international initiatives has been another priority. All Yale undergraduates now have the opportunity to study or participate in internships abroad. Several years ago, need-based financial aid became available for all international students in Yale College as it has been for U.S. citizens and permanent residents. Mr. Levin has established numerous educational and research partnerships in China and India. On March 31, 2011, the National University of Singapore (NUS) and Yale announced that Yale-NUS College would be established in Singapore, providing a new model of liberal arts education for Asia. Mr. Levin is recognized as an advocate and leader of the role of higher education in local and global sustainable development. He established an Office of Sustainability in 2005, and that year endorsed an aggressive greenhouse gas reduction target and strategy for the University. Mr. Levin serves on President Obama’s Council of Advisors for Science and Technology. He is a trustee of the Hewlett Foundation, a director of ClimateWorks, American Express, and C3, and a member of the National Committee on United States-China Relations. He served on a bipartisan commission to recommend improvements in the nation’s intelligence capabilities and he co-chaired a major review of the nation’s patent system for the National Academy of Sciences. President Levin holds honorary degrees from Harvard, Princeton, Oxford, Peking, Tokyo, and Waseda universities and Chinese University of Hong Kong. He is a Fellow of the American Academy of Arts and Sciences. Richard Levin and his wife, Jane, have lived in New Haven throughout their more than 40 years at Yale. They have four children and seven grandchildren. Douglas Rae (moderator) Douglas Rae is a student of the interface between business and government. He has served on the Yale faculty since 1967, chairing the political science department during the 1980s. He took public service leave in 1990 and 1991 to serve as chief administrative officer of New Haven during a crisis period. He has been awarded a Guggenheim Fellowship, was a fellow of Stanford’s Center for Advanced Study in the Behavioral Sciences, a fellow of the Netherlands Institute for Advanced Study, and has received numerous honors and prizes for his research. He has consulted widely and variously to the parliaments of Spain, Italy, & the Netherlands Antilles, select corporate leaders, to numerous American cities and universities, and to the BBC. At Yale, he has held leadership positions and board memberships with the University Library, Yale University Press, the Institution for Social and Policy Studies, the Division of Social Sciences, the Department of Athletics, and Yale SOM. In 2010, Mr. Rae was awarded the Mory's Cup in recognition of his service to Yale.

Das zur Bekämpfung von D. gallinae beim Geflügel kürzlich entwickelte Phoxim 50%-Emulsionskonzentrat (ByeMite®, Bayer HealthCare, Animal Health Division) wurde gegen D. gallinae geprüft. Im Vergleich zu einem unbehandelten Kontrollstall mit 1368 Käfigen (5438 Tiere) wurde ein Stall mit 2112 Käfigen (8138 Tiere) gemäss den Angaben des Herstellers behandelt. In den 49 Tagen der Studie wurde der Milbenbefall regelmäßig untersucht. Beide Betriebe waren natürlich mit D. gallinae infestiert. Im Behandlungsbetrieb erfolgte die zweimalige Ausbringung einer 2000ppm Phoxim – Gebrauchslösung im Abstand von 7 Tagen. Die dafür entwickelten Milbenfallen wurden in beiden Betrieben an den Tagen -1, 2, 6, 9, 13, 20, 34 and 48 aufgestellt und nach 24 Stunden eingesammelt. Die gefangenen Milben wurden hinsichtlich ihrer Entwicklungsstufen (Eier, Larven, Nymphen, Adulte) differenziert und gezählt. Bereits 3 Tage nach der erstmaligen Ausbringung der Spraylösung war die Wirksamkeit gegen D. gallinae > 96%. Nach der zweiten Sprühung betrug die Wirksamkeit >99%. Die Milbenpopulation im unbehandelten Kontrollbetrieb stieg im Kontrollbetrieb in der Vergleichsperiode um mehr als 400% an. Daraus kann geschlossen werden, dass die 2 Sprühungen hochwirksam gegen D. gallinae sind. In der zweiten Studie wurde zur Erfassung der Epidemiologie in einem Betrieb mit Volieren – und in einem Betrieb mit Bodenhaltung ein Milben – Monitoring mittels Milbenfallen durchgeführt. Die Untersuchung begann in der Serviceperiode vor Einstallung der Junghennen und endete mit der Ausstallung der Legehennen. Im ein- bis zweiwöchigen Intervall wurden in den Betrieben Fallen aufgestellt und jeweils nach 24 Stunden eingesammelt. Die Ergebnisse zeigten, dass D. gallinae bereits 26 und 39 Tage nach der Neueinstallung in den gewählten Betrieben nachgewiesen werden konnte. Die Milbenpopulation stieg mit gewissen Schwankungen kontinuierlich nach erstmaliger Feststellung, bis zur zwingend notwendigen Behandlung an. Aufgrund der massiven Belästigung des Stallpersonals musste an den Tagen 227/ 234 und an den Tagen 278/ 285 eine Behandlung mit einer 2000ppm Phoxim – Gebrauchslösung gegen den Befall mit D. gallinae, im Abstand von 7 Tagen durchgeführt werden. Die Phoxim - Sprühung der Voliere bewirkte eine Milbenreduktion zwischen 90 und 99,3%. Im Betrieb mit Bodenhaltung zeigte sich eine Reduktion der Milben zwischen 94,5 und 97%. In beiden Studien konnte keine Auswirkung des Milbenbefalls auf die täglich verendeten Legehennen und die Legeleistung festgestellt werden.